|1.||Naoe, Tomoki: 2 articles (01/2014 - 03/2010)|
|2.||Ohtake, Shigeki: 2 articles (01/2014 - 03/2010)|
|3.||Enomoto, Sanae: 2 articles (09/2004 - 01/2002)|
|4.||Numaoka, Hideharu: 2 articles (09/2004 - 01/2002)|
|5.||Sugawara, Takeshi: 2 articles (09/2004 - 01/2002)|
|6.||Ishida, Yoji: 2 articles (09/2004 - 01/2002)|
|7.||Murai, Kazunori: 2 articles (09/2004 - 01/2002)|
|8.||Chen, Xu: 1 article (02/2015)|
|9.||Zheng, Jin-Pu: 1 article (02/2015)|
|10.||Lin, Rong: 1 article (02/2015)|
|1.||Acute Promyelocytic Leukemia
02/10/2011 - "The expression of CD56 antigen in acute promyelocytic leukemia (APL) blasts has been associated with short remission duration and extramedullary relapse. "
09/01/2004 - "The biological significance of CD56 antigen expression in patients with acute promyelocytic leukemia (APL) has been under investigation. "
09/01/2004 - "Clinical and biological significance of CD56 antigen expression in acute promyelocytic leukemia."
01/01/2002 - "We describe an elderly patient with acute promyelocytic leukemia (APL), whose leukemic cells expressed CD56 antigen at relapse but not at diagnosis. "
|2.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
12/01/1993 - "In the present study, the expression of two NK-associated antigens (CD56 and CD16) together with six 'classically' considered lymphoid-related markers (TDT,CD19,CD10,CD7,CD2,CD4) has been analyzed by appropriate dual combinations in 265 acute myelogenous leukemia (AML) patients. "
09/01/2012 - "Prognostic significance of CD56 antigen expression in patients with acute myeloid leukemia."
01/01/2011 - "The expression of CD56 antigen is associated with poor prognosis in patients with acute myeloid leukemia."
01/01/2011 - "The expression of the CD56 antigen is associated with poor prognosis in patients with acute myeloid leukemia."
09/01/2010 - "CD56 antigen expression and hemophagocytosis of leukemic cells in acute myeloid leukemia with t(16;21)(p11;q22)."
06/01/2008 - "In this study, the expression frequency and stability of 2 potential therapeutic targets, CD20 and CD52, along with the frequently aberrantly expressed CD56 antigen, were evaluated by flow cytometric analyses in 56 patients with plasma cell myeloma. "
02/01/2015 - "CD45/SSC and CD38(+)/CD138(+) gating technique can accurately gate multiple myeloma cell sets which need analysis, the majority of myeloma cells expreses CD138, CD38, CD56 antigens. "
11/01/1991 - "Recently we reported the expression of the human natural killer cell associated antigen CD56 (Leu 19/NKH1) in plasma cells of a majority of multiple myeloma (MM) patients. "
07/15/1990 - "Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19)."
03/01/2010 - "These findings suggest that extramedullary involvement of myeloid/NK cell precursor acute leukemia is not directly derived from the presence of CD7 and CD56 antigens on leukemic cells. "
01/01/2014 - "We assessed the clinical significance of CD56 antigen in 239 APL patients prospectively treated with all-trans retinoic acid and chemotherapy according to the Japan Adult Leukemia Study Group APL97 protocol. "
04/01/2001 - "Immunophenotypic analysis revealed that blast cells were positive for myeloid antigens (CD13, CD33), and natural killer (NK) cell antigen (CD56), but negative for T-cell antigens (CD2, CD5, CD7), B-cell antigens (CD19, CD20), CD34, and HLA-DR. The case was diagnosed as secondary myeloid/NK cell acute leukemia following non-Hodgkin's lymphoma. "
07/01/2002 - ""Natural killer" (NK) cell antigens CD56, CD57 and others are expressed on breast and lung tumor cells as well as sea urchin coelomocytes."
06/01/2002 - "Diagnosis is primarily based on a particular immunophenotype with tumor cells expressing CD4 and CD56 antigens in the absence of common lymphoid or myeloid lineage markers. "
07/01/1999 - "Surface marker analysis revealed that the tumor cells had CD5, CD7, CD33, CD34, and CD56 antigens but lacked other T-cell, and B-cell markers. "
02/15/1991 - "Expression of the natural killer cell-associated antigens CD56 and CD57 in human neural and striated muscle cells and in their tumors."
09/01/1986 - "The precursor of this effector population also expressed the phenotype CD3-, Leu-19+. Peripheral blood CD3+ T lymphocytes contributed little to the LAK phenomenon, although low levels of non-MHC restricted cytotoxicity against hematopoietic tumor cell targets were mediated by a subset of CD3+ T lymphocytes that coexpressed the Leu-19 antigen. "
|1.||CD3 Antigens (CD3 Complex)
|2.||Tretinoin (Retinoic Acid)
|3.||Neural Cell Adhesion Molecules (Neural Cell Adhesion Molecule)
|5.||gamma-delta T-Cell Antigen Receptors (T-Cell Receptor delta-Chain)
|6.||HLA-DR Antigens (HLA-DR)
|7.||DNA (Deoxyribonucleic Acid)
|10.||Keratin-20 (Cytokeratin 20)
|1.||Drug Therapy (Chemotherapy)
|2.||Bone Marrow Transplantation (Transplantation, Bone Marrow)